Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
None (23) ·
Compazine (1) ·
Fanapt (1) ·
Feosol, Fer-In-Sol, Slow Fe; mostly generic and OTC (1) ·
Folvite; mostly generic (1) ·
Geodon (1) ·
Inapsine (1) ·
Invega (1) ·
Latuda (1) ·
Loxitane (1) ·
Many OTC and Rx; Nascobal (intranasal); generic injection (1) ·
Mellaril (1) ·
Moban (1) ·
Navane (1) ·
Orap (1) ·
Prolixin (1) ·
Saphris (1) ·
Stelazine (1) ·
Thorazine (1) ·
Trilafon (1)
classes: (Click arrow to add another value)
mechanism:
None (3) ·
Apomorphine and nuciferine; dopaminergic activity (1) ·
Butyrophenone D2 antagonist (1) ·
Contains atropine, scopolamine, hyoscyamine (1) ·
Contains bufotenin and DMT (1) ·
Contains harmine, harmaline, tetrahydroharmine (1) ·
Contains ibogaine; kappa-opioid agonist (1) ·
Contains LSA (2) ·
Contains mescaline (2) ·
Contains muscimol and ibotenic acid (1) ·
Contains psilocybin and psilocin (1) ·
Contains salvinorin A (1) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
DMT + MAOI (harmine/harmaline); 5-HT2A agonist (1) ·
DMT-containing plant used in psychedelic preparations (1) ·
Kavalactones; GABAA modulator; sigma receptor activity (1) ·
Mechanism incompletely understood (1) ·
Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
Partial MAOI; anticholinergic effects (1) ·
Partial mu-opioid receptor agonist; alpha-2 agonist (1) ·
Phenothiazine D2 antagonist (5) ·
Potent mu-opioid receptor agonist (1) ·
Reversible MAO-A inhibitor; beta-carboline (1) ·
Reversible MAO-A inhibitor; NMDA antagonist; beta-carboline (1) ·
Thioxanthene D2 antagonist (1) ·
Weak serotonin reuptake inhibitor; beta-carboline (1)
uses:
None (39) ·
'"`UNIQ--vote-0000059A-QINU`"', '"`UNIQ--vote-0000059B-QINU`"' (1) ·
'"`UNIQ--vote-000005B3-QINU`"', '"`UNIQ--vote-000005B4-QINU`"', '"`UNIQ--vote-000005B5-QINU`"', '"`UNIQ--vote-000005B6-QINU`"' (1) ·
'"`UNIQ--vote-00000607-QINU`"', '"`UNIQ--vote-00000608-QINU`"', '"`UNIQ--vote-00000609-QINU`"', '"`UNIQ--vote-0000060A-QINU`"' (1)
starting dose:
None (39) ·
0.4 mg PO daily (general prevention); 0.8-1 mg/d in pregnancy; 4 mg/d for women with prior NTD-affected pregnancy; 1 mg/d during methotrexate therapy (1) ·
325 mg PO daily to TID (=65 mg elemental iron/tablet); alternate-day dosing is now favored by hepcidin physiology for better absorption with less GI burden (1) ·
Replacement: 1000 mcg IM daily for 1 week, then weekly for 4 weeks, then monthly; or 1000-2000 mcg PO daily (effective even in pernicious anemia via passive diffusion); intranasal 500 mcg weekly (1)
preparations:
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
pregnancy:
None (39) ·
Routinely supplemented in pregnancy and preconception to prevent neural tube defects.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Routinely supplemented in vegan pregnancies and pernicious anemia.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Routinely used; iron requirements rise substantially in pregnancy and lactation.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 42 results in range #1 to #42.